Joylux Alternatives: Best Options for Every Intimate Wellness Use Case

What Joylux Actually Is (and What It Isn't)

Joylux produces the vFit Plus, a wearable device you insert vaginally for about eight minutes per session. It combines low-level red light (650 nm), gentle heat, and sonic vibration. The company positions it for vaginal dryness, laxity, and sexual satisfaction. The price sits around $495 for the device alone.

The critical detail: the vFit Plus carries FDA 510(k) clearance as a general wellness device, not as an FDA-cleared or FDA-approved medical device for treating GSM or any clinical condition. That distinction matters for insurance, for efficacy expectations, and for how you weigh it against prescription options.

What the company's own data shows

Joylux has published one manufacturer-sponsored, 30-woman, open-label study. Participants reported improvements in vaginal lubrication and sexual satisfaction scores after 60 days. No control arm existed. Placebo effects in sexual-health device trials are well-documented and can be large. Independent peer-reviewed replication is not yet available as of mid-2025.

What GSM actually is

Genitourinary syndrome of menopause (GSM) is the preferred clinical term for vaginal dryness, burning, irritation, urinary urgency, and dyspareunia driven by estrogen decline. Roughly 45% of postmenopausal women report bothersome GSM symptoms, yet fewer than a quarter seek treatment. GSM also affects women on aromatase inhibitors for breast cancer, those who are postpartum and breastfeeding, and those with premature ovarian insufficiency.

Why Women Look for Joylux Alternatives

Cost is one reason. At $495 upfront, the vFit Plus is not inexpensive, and there are no refills or consumables beyond replacement bulbs that Joylux sells separately. But cost is not the only consideration.

You might need something stronger. Red light and mild heat are not the same physiological stimulus as estrogen. If your vaginal wall has thinned significantly or your pH has shifted above 5.5 (the threshold associated with recurrent UTIs and symptomatic GSM), a prescription treatment has far more published efficacy data behind it.

You might have contraindications to estrogen. Women with estrogen-receptor-positive breast cancer history often avoid systemic or even topical estrogen, which is exactly the population most likely to have severe GSM from chemotherapy or aromatase inhibitor use. This population needs carefully chosen alternatives.

You might want in-office energy-based treatment. In-office fractional CO2 laser or radiofrequency devices deliver a different and more intense stimulus, with longer-studied outcomes.

The WomanRx Use-Case Matching Framework below walks through each symptom cluster and the best-matched option by evidence strength.

Use Case 1: Vaginal Dryness and GSM

Prescription options outperform devices on clinical endpoints

Vaginal estradiol at low doses (the 10 mcg Vagifem tablet or the 4 mcg Yuvafem insert, or the 0.01% Estrace cream) is the best-studied treatment for GSM. The 2023 Menopause Society (NAMS) position statement on GSM states: "Low-dose vaginal estrogen is effective and safe for most women with GSM and is not substantially absorbed systemically at approved doses." That level of endorsement does not exist for any at-home light device.

Vaginal DHEA (prasterone, brand name Intrarosa) 6.5 mg nightly is a non-estrogen option. It converts locally to both estrogen and testosterone in vaginal tissue. The phase 3 AMETHYST trial demonstrated significant improvements in the Most Bothersome Symptom (MBS) of dyspareunia and vaginal dryness versus placebo at 12 weeks, with minimal systemic absorption. For women who prefer to avoid estrogen by name, this is a strong option.

Ospemifene (Osphena) 60 mg oral daily is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in vaginal tissue. It is taken by mouth, which some women prefer. The EASE trial showed statistically significant improvement in vaginal maturation index and MBS scores at 12 weeks versus placebo.

OTC lubricants and moisturizers as first-line for mild symptoms

If your symptoms are mild, start with a pH-balanced vaginal moisturizer (Revaree, a hyaluronic acid suppository, or Replens long-acting moisturizer) used 3 times per week, plus a silicone or water-based lubricant during sex. These cost $15 to $40 per month. The Cochrane review on vaginal atrophy treatments notes that moisturizers reduce symptom scores comparably to low-dose vaginal estrogen in the short term for mild-to-moderate dryness, though the evidence base is smaller.

Where vFit Plus sits in this hierarchy

For mild-to-moderate vaginal dryness in a woman who has contraindications to both estrogen and DHEA (for example, certain hormone-sensitive cancers) and who cannot access or afford in-office laser, a home red-light device like vFit Plus is a reasonable experiment. It is not a first-line option when prescription treatments are available and not contraindicated.

Use Case 2: Pelvic Floor Tone and Mild Stress Urinary Incontinence

The evidence for energy-based devices at home

Pelvic floor muscle training (PFMT) remains the ACOG-recommended first-line treatment for stress urinary incontinence (SUI) in women. A supervised program with a pelvic floor physical therapist achieves, on average, a 70% reduction in leakage episodes in women with SUI. That datum comes from the PFMT systematic review of 31 trials.

Joylux does not specifically claim to treat incontinence, and the vFit Plus should not be substituted for pelvic floor PT.

Devices that do target pelvic floor tone

The Elvie Trainer and Perifit are biofeedback Kegel devices ($50 to $199) that use real-time app feedback to guide correct muscle contraction. These are better studied than red-light devices for improving pelvic floor strength.

The Emsella chair (BTL Aesthetics) delivers high-intensity focused electromagnetic (HIFEM) energy to contract pelvic floor muscles. One randomized controlled trial in the Journal of Women's Health found that 6 Emsella sessions (twice weekly) reduced incontinence episodes by 75% at 6 months versus baseline. It is an in-office treatment costing $1,500 to $3,000 for a full course.

Use Case 3: Sexual Satisfaction and Arousal Difficulty

Separating device effects from the underlying cause

Sexual dissatisfaction in midlife and beyond usually has several intersecting causes: GSM-related pain with penetration, reduced genital blood flow from estrogen loss, relationship factors, sleep disruption, mood changes, and sometimes reduced androgens. A device that addresses one variable without assessing the others will underperform.

For women with hypoactive sexual desire disorder (HSDD), the FDA-approved options are flibanserin (Addyi) 100 mg nightly oral (for premenopausal women) and bremelanotide (Vyleesi) 1.75 mg subcutaneous injection on demand (approved regardless of menopausal status). Neither is a device. Testosterone therapy, though not FDA-approved specifically for HSDD in women, has the largest evidence base for desire in postmenopausal women according to the 2019 Global Consensus Position Statement on Testosterone for Women, published jointly by the Endocrine Society, ISSWSH, and others.

For arousal and genital blood flow specifically, the EROS clitoral therapy device (FDA-cleared) uses vacuum suction to increase clitoral engorgement. It has a published RCT showing improvement in arousal and lubrication scores.

Vibrators and wand massagers improve genital blood flow through mechanical stimulation. The data on this are limited to small studies but physiologically plausible.

The vFit Plus, with its vibration and warmth components, may overlap mechanically with this use case. The manufacturer's own data did show improved arousal scores, but again, no control arm.

Use Case 4: In-Office Energy-Based Vaginal Rejuvenation

CO2 laser (MonaLisa Touch, FemTouch)

Fractional CO2 laser delivers controlled thermal injury to vaginal mucosa, stimulating collagen remodeling and improving glycogen content of vaginal epithelium. The ACOG Committee Opinion 795 (2020) states that "energy-based devices are not FDA approved for treating GSM and long-term data are limited," urging that these procedures be performed only in the context of informed consent and ideally clinical trials.

A 12-month randomized trial published in JAMA comparing fractional CO2 laser to sham in 78 postmenopausal women with GSM found no statistically significant difference between groups on the vaginal symptom index at 12 months. This trial generated significant debate but is the most rigorous evidence available.

Contrast that with the 2023 NAMS GSM position statement, which notes that some smaller trials show symptom benefit and that larger sham-controlled trials are needed before laser or RF can be recommended as standard of care.

Cost for a CO2 laser series: $900 to $3,000 per session, typically 3 sessions needed.

Radiofrequency (ThermiVa, Votiva)

Radiofrequency devices heat connective tissue to stimulate neocollagenesis. The evidence base is smaller and mostly open-label. One 2017 pilot RCT in the Journal of Sexual Medicine showed improvement in vaginal dryness and sexual function scores at 6 months in 30 postmenopausal women. Sample sizes remain too small for definitive conclusions.

How vFit Plus compares to in-office options

The vFit Plus uses red light at a much lower power density than in-office laser and heat at a much lower temperature than RF. It is a less intense stimulus. That may mean a better safety profile at home but also means expecting a less dramatic tissue response. For women who cannot afford or access in-office treatment and whose symptoms are mild, it occupies a reasonable niche. For moderate-to-severe GSM with significant tissue changes, in-office options or prescription therapy are more appropriate.

Use Case 5: Breast Cancer Survivors with GSM

GSM is especially prevalent and often severe in breast cancer survivors, because chemotherapy can cause premature ovarian insufficiency and aromatase inhibitors dramatically suppress estrogen. Up to 90% of women on aromatase inhibitors report urogenital symptoms.

Systemic estrogen is generally contraindicated in ER-positive breast cancer survivors. Low-dose vaginal estrogen carries theoretical concern about systemic absorption, though most oncology guidelines consider it acceptable when non-hormonal options fail and after oncologist discussion.

Non-hormonal options with meaningful evidence in this population:

• Vaginal DHEA (Intrarosa): systemic estrogen levels in trials remained within postmenopausal range; the AMETHYST trial included women with a history of breast cancer in sensitivity analyses.
• Ospemifene: the ER-positive breast cancer population was excluded from the key trials; use requires oncologist input.
• Hyaluronic acid moisturizers: evidence from a 2019 RCT in Menopause shows comparable symptom relief to low-dose vaginal estrogen at 8 weeks in GSM.
• vFit Plus or similar home red-light devices: no systemic hormonal exposure, so no theoretical oncologic concern. The safety profile in breast cancer survivors is acceptable by mechanism. Efficacy data in this population specifically are absent.

For breast cancer survivors with GSM who cannot use any hormonal option, a home red-light device plus hyaluronic acid moisturizer is a reasonable non-hormonal combination while awaiting better data.

Life-Stage Guide: Who Benefits Most from Which Option

Reproductive years with PCOS or hormonal acne

Vaginal dryness during reproductive years usually reflects a specific cause: hormonal contraception (particularly progestin-only pills or the levonorgestrel IUD), antidepressants, or antihistamines. Address the root cause first. Switching to a lower-androgenic pill or adding vaginal moisturizer is more targeted than a device.

Trying to conceive or pregnant

Avoid any intravaginal energy device during pregnancy. No safety data exist for red light, heat, or vibration devices used vaginally during pregnancy. Avoid vFit Plus (or any comparable device) if you are pregnant or attempting conception via IVF with a recent embryo transfer. Vaginal lubricants during the conception window should be fertility-friendly (pH 7.0, iso-osmolar), such as Pre-Seed.

Postpartum and breastfeeding

Postpartum vaginal dryness and laxity are driven by the hypoestrogenic, high-prolactin state of lactation. This is the second most common time, after menopause, for GSM-like symptoms. Low-dose vaginal estrogen in lactating women has minimal systemic absorption and is considered compatible with breastfeeding by LactMed, though the lowest effective dose for the shortest needed duration is recommended. For postpartum pelvic floor laxity specifically, pelvic floor physical therapy starting at 6 to 8 weeks postpartum is the standard of care.

Perimenopause

Hormonal fluctuation during perimenopause means vaginal symptoms may be intermittent and correlated with cycle phase. Topical vaginal estrogen or a moisturizer is often sufficient. A pelvic floor assessment is worth adding if you also have leakage or prolapse symptoms.

Postmenopause

This is the primary target population for Joylux and for most GSM treatments. Start with prescription low-dose vaginal estrogen if not contraindicated. Layer in a moisturizer. If you prefer to avoid all hormonal exposure or have tried and stopped vaginal estrogen, a home red-light device is a reasonable adjunct, not a replacement.

Is Joylux Legit? A Candid Assessment

Joylux is a real company with a real device. The vFit Plus is not a scam. Red light at 650 nm has demonstrated biological effects on cellular mitochondrial function in skin tissue studies, and gentle heat increases blood flow. The mechanism is not implausible.

What Joylux is not: a replacement for prescription therapy, a cure for GSM, or a device with the same evidence standard as FDA-approved drugs. The published study is small, uncontrolled, and manufacturer-sponsored. The $495 price tag is significant for an unproven intervention.

A 2021 systematic review in Photobiomodulation, Photomedicine, and Laser Surgery found that low-level laser/light therapy improved wound healing and collagen synthesis in mucosal tissue, providing some biological plausibility for vaginal applications. But that review covered wound healing contexts, not GSM specifically.

The honest answer: if you have mild symptoms, no access to or interest in prescription treatment, and $495 to spend, vFit Plus may produce modest improvement in lubrication and comfort. You should not expect it to perform at the level of vaginal estradiol for moderate-to-severe GSM.

Pregnancy and Lactation Safety Note

This article covers devices and treatments, not a single drug. Pregnancy and lactation considerations vary by specific option:

Vaginal estradiol cream or inserts: avoid in the first trimester. Use with caution in later pregnancy only if clearly indicated. At standard low doses, systemic absorption is low. LactMed classifies low-dose vaginal estradiol as likely compatible with breastfeeding but recommends monitoring infant growth if used long-term during lactation.

Vaginal DHEA (Intrarosa): not studied in pregnancy. Avoid in pregnancy and during breastfeeding due to unknown fetal and infant exposure risk.

Ospemifene (Osphena): contraindicated in pregnancy. It is a SERM with potential teratogenic and embryotoxic effects based on animal data. Women of reproductive age must use effective contraception while taking ospemifene. Avoid during breastfeeding.

Flibanserin (Addyi): contraindicated in pregnancy and approved only for premenopausal women with acquired, generalized HSDD. Avoid alcohol (boxed warning). Not studied in lactation; avoid.

vFit Plus and similar home energy devices: no human pregnancy or lactation safety data exist. Avoid during pregnancy. During breastfeeding, the device does not deliver systemic exposure, but intravaginal use immediately postpartum (before 8 weeks) is not recommended before pelvic floor clearance from your provider.

Alternatives at a Glance: Summary Table

| Use Case | Best Prescription Option | Best OTC/Device Option | Evidence Level | |---|---|---|---| | Moderate-severe GSM | Vaginal estradiol 10 mcg | Hyaluronic acid suppository | Strong (RCTs) | | GSM, estrogen-avoidant | Vaginal DHEA (Intrarosa) | Replens moisturizer | Moderate (RCTs) | | Dyspareunia only, oral preferred | Ospemifene (Osphena) | Silicone lubricant | Moderate (RCTs) | | Low sexual desire | Testosterone (off-label) or flibanserin | EROS device, vibrator | Moderate to low | | Stress incontinence | Pelvic PT (first-line) | Elvie/Perifit biofeedback | Strong for PFMT | | Mild GSM, all options refused | N/A | vFit Plus or similar | Low (open-label only) | | In-office tone/rejuvenation | N/A (Emsella for SUI) | N/A | Moderate, evolving |